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Background: Vitamins are typical ligands that play critical roles in various metabolic processes. The accurate
identification of the vitamin-binding residues solely based on a protein sequence is of significant importance for
the functional annotation of proteins, especially in the post-genomic era, when large volumes of protein sequences
are accumulating quickly without being functionally annotated.
Results: In this paper, a new predictor called TargetVita is designed and implemented for predicting protein-vitamin
binding residues using protein sequences. In TargetVita, features derived from the position-specific scoring matrix (PSSM),
predicted protein secondary structure, and vitamin binding propensity are combined to form the original feature space;
then, several feature subspaces are selected by performing different feature selection methods. Finally, based on
the selected feature subspaces, heterogeneous SVMs are trained and then ensembled for performing prediction.
Conclusions: The experimental results obtained with four separate vitamin-binding benchmark datasets demonstrate
that the proposed TargetVita is superior to the state-of-the-art vitamin-specific predictor, and an average improvement
of 10% in terms of the Matthews correlation coefficient (MCC) was achieved over independent validation tests.
The TargetVita web server and the datasets used are freely available for academic use at http://csbio.njust.edu.
cn/bioinf/TargetVita or http://www.csbio.sjtu.edu.cn/bioinf/TargetVita.
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Functional positions in a protein are residues that play
more critical roles than other residues and enable the pro-
tein to perform specific biological functions, such as cap-
turing drugs [1], binding ligands [2], and interacting with
other proteins [3]. However, functionally annotated pro-
teins still account for only a small portion of sequenced
proteins, and the gap between annotated and sequenced
proteins is ever-increasing with the rapid development of
advanced sequencing technology and concerted genome
projects [4]. Automated computational methods for the
prediction of protein functional positions are urgently
needed and have become a hotspot in bioinformatics re-
search. During the past decades, machine-learning-based* Correspondence: njyudj@njust.edu.cn; hbshen@sjtu.edu.cn
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unless otherwise stated.computational methods have been extensively applied to
various protein functional position prediction problems
[5-7].
Protein-ligand interaction is one of the most important
protein functions and plays vital roles in virtually all bio-
logical processes [2,8,9]. Considerable effort has been
made to design effective methods for protein-ligand bind-
ing residue (site) prediction, and much progress has been
made in this area [10]. In the early stage, general-purpose
protein-ligand predictors, which predict ligand binding
sites (pockets) regardless of ligand types, dominate in the
fields of protein-ligand binding site prediction. Such pre-
dictors include LIGSITE [11], CASTp [12], SURFNET
[13], POCKET [14], fpocket [15], Q-SiteFinder [16], and
SITEHOUND [17]. Later, researchers observed that
protein-ligand binding sites (pockets) vary significantly in
their roles, sizes, and distributions for different types of
protein-ligand interactions, and different ligands tend to
bind diverse types of residues with prominent specificitiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ligand-specific predictors, which are specifically de-
signed to predict binding residues or sites for certain
ligand types, such as NsitePred [20] and TargetS [21]
for protein-nucleotide binding prediction, FINDSITE-
metal [22] and CHED [23] for protein-metal binding
prediction, MetaDBSite [24] and DNABR [25] for
protein-DNA binding prediction, protein-drug binding
prediction [26], and others. These studies have shown
that ligand-specific predictors are often superior to gen-
eral-purpose predictors and are a promising route for
improving the performance of protein-ligand prediction
[20,21].
Vitamins are typical ligands and play critical roles in
various metabolic processes [27-29]. However, to the best
of our knowledge, minimal work has been performed to
design a specific predictor for predicting protein-vitamin
binding residues. Recently, Panwar et al. [30] published
their pioneering work on protein-vitamin binding predic-
tion and a predictor, called VitaPred, was implemented.
VitaPred [30] is a sequence-based ligand-specific predictor
specifically designed for predicting protein-vitamin
binding residues, and it consists of four independent
prediction modules for predicting vitamin, vitamin-A,
vitamin-B, and pyridoxal-5-phosphate (vitamin-B6) bind-
ing residues. VitaPred encodes each residue into a 340-D
feature vector by applying a sliding window to the
position-specific scoring matrix (PSSM) of a protein se-
quence; then, a support vector machine (SVM) is trained
on the set of feature vectors of all the training residues. In
the prediction stage, the feature vector of each residue in
a query sequence is fed into the trained SVM, and the
binding propensity of each residue is obtained; finally, a
threshold is used to determine whether a residue is
vitamin-interacting. Although VitaPred achieved great
success in predicting protein-vitamin binding residues,
there is still room for further improving the prediction
performance: first, only the PSSM-derived feature was
used in VitaPred, and other valuable features (e.g., protein
secondary structure) were not well considered; second,
the PSSM feature constructed in VitaPred may contain re-
dundant information, which is useless or even harmful for
performing prediction.
This paper follows the pioneering work of Panwar et al.
[30] and aims to further improve the performance
of protein-vitamin binding residue prediction. A new
predictor, called TargetVita, which utilises multiple
sequence-derived features and heterogeneous SVMs en-
semble based on feature selection, is developed. In
TargetVita, three different types of features (i.e., a
position-specific scoring matrix feature, a predicted
secondary structure feature, and a vitamin binding pro-
pensity feature) are combined to form the original fea-
ture space; then, three feature selection methods areperformed on the original feature space to extract
three different feature subspaces, and heterogeneous
SVMs are trained on the reduced feature subspaces. Fi-
nally, when performing prediction, the vitamin-binding
propensity of each residue in a query sequence is
predicted by averaging the outputs of the three
trained heterogeneous SVMs. Experimental results
obtained with four separate vitamin-binding bench-
mark datasets demonstrate that the proposed Target-
Vita is superior to VitaPred [30] and an average
improvement of 10% in terms of the Matthews correlation




In this study, four benchmark datasets created by Panwar
et al. [30] were utilised to evaluate the efficacy of the pro-
posed method. For convenience, the four benchmark data-
sets are denoted as DVI (dataset of vitamin-interacting
proteins), DVAI (dataset of vitamin-A-interacting pro-
teins), DVBI (dataset of vitamin-B-interacting proteins),
and DPLPI (dataset of pyridoxal-5-phosphate interacting
proteins), respectively.
Each benchmark dataset was constructed with a strin-
gent procedure as follows [30]: taking DVI as an example,
1061 PDB IDs of proteins that make contact with vitamins
were first collected from SuperSite documentation [31];
then, the sequences of all chains of these 1061 PDB
IDs were downloaded from the Protein Data Bank [32].
Among the obtained sequences, 2720 sequences were
finally chosen according to the results returned from
the Ligand Protein Contact (LPC) web server [33] by
taking 1061 PDB IDs as inputs. Then, a threshold of
5.0 Å was used to determine the vitamin-interacting
residues: a residue was considered to be vitamin-
interacting if the closest distance between atoms of the
protein and the partner vitamin was within the thresh-
old (5.0 Å) [30]; finally, the maximal pairwise sequence
identity of the vitamin-binding sequences obtained in
the above steps was further reduced to 25% by using
BLASTCLUST [34], and the obtained 187 vitamin-
interacting chains with 30156 vitamin-binding residues
constituted the DVI. Similarly, DVAI, DVBI, and DPLPI,
which consist of 31, 141, and 71 non-redundant se-
quences, respectively, were also constructed by repeating
the above-mentioned steps.
Four different independent validation datasets for DVI,
DVAI, DVBI, and DPLPI, which consist of 46, 15, 27,
and 16 non-redundant sequences, respectively, were also
constructed [30]. In addition, to guarantee the independ-
ence of the independent validation subset, the maximal
pairwise sequence identity of each independent valid-
ation dataset is less than 25%, and any sequence in an
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the sequences in the corresponding training dataset.
Table 1 summarises the detailed compositions of the
four benchmark datasets. Details for constructing these
datasets can be found in [30].
To evaluate the performance of TargetVita with non-
vitamin binding proteins, we also constructed a non-
vitamin binding dataset, denoted as NVD, from BioLip
[35], which is the most recently released semi-manually
curated database for biologically relevant ligand–protein
interactions. We constructed the NVD as follows: First,
all the sequences that do not interact with vitamins are
extracted from BioLip; then, the maximal pairwise se-
quence identity of the extracted protein sequences is
culled to 30% by using CD-Hit [36] program, and the re-
duced dataset is obtained. Moreover, if a given sequence
in the reduced dataset shares >30% identity with a se-
quence in the training dataset DVI, we remove the se-
quence from the reduced dataset. Finally, the remaining
6676 sequences (with 1852390 residues) constitute
NVD.
All the datasets used in this study are included in
Additional file 1.
Feature representation
Feature representation is a critical step in designing a
machine-learning-based predictor. In this study, mul-
tiple sequence-derived features, which potentially have
a positive impact on the performance improvement of
protein-vitamin binding residue prediction, are ex-
tracted and combined to form an informative feature
space.
1) Position-specific scoring matrix (PSSM)
Previous studies have demonstrated that the evolution-
ary information reflected by a position specific scoring
matrix (PSSM) is a powerful feature source in many
bioinformatics problems including protein-ligand bind-
ing predictions [20,21,37-40]. In view of this, PSSM was
also taken as a feature source in this study. First, we ob-
tained the original PSSM of a sequence by executingTable 1 Compositions of the training datasets and the corres
of vitamin-interacting benchmark datasets
Dataset Training Dataset
No. of Sequences (numP, numN)*
DVI 187 (3016, 62122)
DVAI 31 (538, 7376)
DVBI 141 (2219, 50179)
DPLPI 71 (1092, 26638)
*numP and numN represent the numbers of positive (binding) and negative (non-bPSI-BLAST [41] to search the Swiss-Prot database
through three iterations with 0.001 as the E-value cut-off
against the sequence; then, each element x contained in
PSSM was normalised by the logistic function f(x) = 1/
(1 + e− x), and the normalised PSSM was obtained. Fi-
nally, the PSSM-based feature vector for each residue
in the query sequence can be extracted with a sliding
window as follows: for a residue at position i of the
query sequence, its feature vector consists of the nor-
malised PSSM elements of the query sequence corre-
sponding to a sequence segment of length W centred
on i. In this study, W, i.e., the size of sliding window,
was set to 17, which has been demonstrated to be a better
choice in VitaPred [30] and several other protein-ligand
binding site prediction studies [37,38]. Consequently, the
dimensionality of the PSSM feature vector of a residue is
17 × 20 = 340.
2) Predicted secondary structures (PSSs)
A fundamental hypothesis for most of the sequence-based
protein attribute predictions is that sequences with similar
structures will have similar functions. Previous studies
have also shown that a close relationship exists be-
tween protein structure and function. Many structural
characteristics, such as secondary structure informa-
tion, have been extensively investigated for the identifi-
cation of protein functional residues (e.g., protein-ligand
binding residues [40,42]). The appropriate utilisation
of protein structural information may potentially help
to improve the performance of protein-ligand binding
prediction, as has been empirically demonstrated in
our recent work [21,38]. Therefore, protein secondary
structure information, predicted from the protein
sequence by performing PSIPRED [43], was used as
another feature source for protein-vitamin binding residue
prediction.
The predicted secondary structure information of a
protein sequence is obtained by applying PSIPRED [43]
software, which predicts the likelihood that a given resi-
due in a protein sequence belongs to one of three sec-
ondary structure classes: coil (C), helix (H), and strandponding independent validation datasets for the 4 types
Independent Validation Dataset Total No.
of
Sequences
No. of Sequences (numP, numN)*
46 (654, 11676) 233
15 (181, 1441) 46
27 (419, 8947) 168
16 (246, 5935) 87
inding) samples, respectively.
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dues, PSIPRED outputs an L × 3 probability matrix,
which represents the predicted secondary structure in-
formation of the protein. Again, a sliding window of size
17 was used to extract the predicted secondary structure
feature of each residue, and the dimensionality of the ex-
tracted PSSs feature vector was 17 × 3 = 51.
3) Vitamin binding propensities (VBPs)
Previous studies have demonstrated that different li-
gands tend to bind different residues [18,19,21]. Panwar
et al. [30] also analysed different protein-interacting
residues of different vitamin classes and observed that
different vitamins tend to bind different residues; this
phenomenon can also be observed within vitamin sub-
classes. Motivated by this observation, we can thus cal-
culate the binding propensities of the 20 native amino
acids for each type of vitamin and then extract a
vitamin-specific 17-D binding propensity feature vector,
denoted as VBP, for each residue in a protein sequence
by concatenating the binding propensities of its neigh-
bouring residues within a window of size 17 centred at
the residue.
Finally, the feature representation of a residue is
formed by serially combining its three corresponding
feature vectors, i.e., PSSM, PSSs, and VBPs, and the
dimensionality of the obtained feature vector is 340 +
51 + 17 = 408-D.
Ensemble multiple heterogeneous subspace SVMs based
on feature selection
After determining the feature representation, prediction
models can be trained on a dataset with machine-
learning algorithms such as SVM, as used in this study.
However, directly training prediction models on the
original feature space is often not the best solution.
One important reason is that redundant information
that has no positive, and sometimes even negative, im-
pact on the prediction performance could potentially
exist. Selection of the most discriminative feature sub-
space from the original feature space may help to im-
prove prediction performance. Accordingly, feature
selection has been a hotspot and is widely used in many
bioinformatics and related fields [44], such as sequence
analysis [45,46] and microarray analysis [47,48]. For
example, our recent work [49] has demonstrated that
the PSSM feature contains redundant information,
which is useless for disulphide connectivity prediction,
and the prediction performance can be further im-
proved when the original PSSM feature is reduced to a
lower but more compact feature subspace via feature
selection.
However, many existing traditional feature selection
methods such as data variance [49], the Fisher score[50], and the Laplacian score [51] are faced with two
deficiencies: first, the importance of features is calcu-
lated individually; thus, the correlation and dependency
of different feature components are neglected. Second,
the dimensionality of the reduced feature subspace needs
to be prescribed in advance of the feature selection
process, which is often difficult or even impossible in
practice.
Recently, we developed a generalised Joint Laplacian
Feature Weights Learning algorithm [52], denoted as
JLFWL, which can effectively address the above-mentioned
two deficiencies. Rather than computing feature weights
one by one, JLFWL automatically determines the opti-
mal size of the feature subspace and selects the best
feature components from the original feature space
by iteratively learning the feature weights jointly and
simultaneously.
Here, we briefly restate JLFWL; details can be found in
[52].
Let matrix X = [x1, x2, ⋯, xM] ∈ R
N × M be a training
dataset, where M is the number of samples, N is the di-
mensionality of features, and xi is the feature vector of the
i-th training sample. Then, the Joint Laplacian Feature
Weights Learning can be summarised in Algorithm 1.
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trol the l22 -norm of w. In this study, ε is set to be 0.5.
Different feature subspaces can be selected from the
original feature space with different feature selection
methods, and the discriminative characteristics of the
obtained feature subspaces may also differ. Prediction
models trained on these different feature subspaces po-
tentially complement each other, which motivates us to
propose an ensemble learning scheme, i.e., a multiple
heterogeneous subspace SVMs ensemble based on fea-
ture selection, as follows:
First, multiple feature subspaces are selected by apply-
ing different feature selection methods; then, based on
these selected feature subspaces, multiple prediction
models, which are termed as heterogeneous models, can
be trained on the same dataset; for a query input,
the final prediction output is obtained by ensembling
the outputs of the trained heterogeneous prediction
models.
To demonstrate the efficacy of the proposed ensem-
ble learning scheme, three feature selection methods
(i.e., our JLFWL together with two traditional feature
selection methods, such as the Fisher score [50] and
Laplacian score [51]) are taken to perform feature
selections, and SVM [53] [54] is used as the base
machine-learning algorithm to train multiple hetero-
geneous prediction models. We locally performed
JLFWL on benchmark datasets and found that the op-
timal dimensionality of the feature subspace, which
is automatically determined by JLFWL, is 386. For
consistency, the dimensionalities of the feature sub-
spaces obtained by Fisher score [50] and Laplacian
score [51] feature selection methods are also set to
be 386.
In this study, C-SVM is used and there are no spe-
cific weights for the three heterogamous SVM models.
Radial basis function is chosen as the kernel function.
The other two parameters, i.e., the regularisation par-
ameter γ and the kernel width parameter σ, are set ac-
cording to the optimisation results from a grid search
strategy in the LIBSVM software.Workflow of the proposed TargetVita
Figure 1 illustrates the workflow of the proposed Target-
Vita. In the training stage, all the feature vectors of the
residues in the training sequences constitute the training
feature vector set; then, L feature subspaces can be se-
lected by performing L different feature selection
methods on the training feature vector set; based on the
selected feature subspace, L heterogamous SVM models
can be trained.
In the prediction stage, for each residue in a query
protein sequence, its PSSM and PSSs feature vectors arefirst extracted by calling PSI-BLAST and PSIPRED and
applying a sliding window technique; then, its PSSM,
PSSs, and VBP feature vectors are combined and filtered
by the L selected feature subspaces, and the L filtered
feature vectors (i.e., feature vectors after feature selec-
tion) are further fed to the L corresponding trained
heterogamous SVMs that predict, for that residue, the
scores related to vitamin interaction; the final score for
the residue is obtained by averaging the predicted scores
of those heterogeneous SVM models. Finally, a threshold
T is used to determine whether the residue is vitamin-
interacting: residues with scores above threshold are
marked as vitamin-interacting.
To help with the visualisation of the prediction results,
MODELLER software [55] is taken to model the protein
3D structure from the sequence, and the predicted
vitamin-interacting residues are highlighted in red on
the modelled 3D structure.
Evaluation indexes
To evaluate the performance of the proposed method,
four routinely used evaluation indexes in this field, i.e.,
Sensitivity (Sn), Specificity (Sp), Accuracy (Acc), and the
Matthews correlation coefficient (MCC) were taken:
Sn ¼ TP
TP þ FN ð1Þ
Sp ¼ TN
TN þ FP ð2Þ
Acc ¼ TP þ TN
TP þ TN þ FP þ FN ð3Þ
MCC ¼ TP⋅TN−FP⋅FNﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TP þ FPð Þ⋅ TP þ FNð Þ⋅ TN þ FPð Þ⋅ TN þ FNð Þp
ð4Þ
where TP, FP, TN, and FN are the abbreviations of True
Positive, False Positive, True Negative, and False Nega-
tive, respectively.
However, these four evaluation indexes are threshold-
dependent, i.e., the values of these indexes vary with the
threshold chosen. Clearly, it is impossible and unneces-
sary to report the values of these indexes under all the
possible thresholds [20,21,37]. In light of this, two
threshold selection strategies, which have been widely
applied in the related fields, were taken to report the
threshold-dependent evaluation indexes, i.e., Sn, Sp, Acc,
and MCC.
Strategy I: Threshold that balances the values of Sn
and Sp
The threshold-dependent evaluation indexes are re-
ported with a threshold, denoted as TBalance, at which
the value of Sn is equal or roughly equal to that of Sp.
For convenience, the evaluation results obtained under
Figure 1 Workflow of the proposed TargetVita. Predicted binding residues, modelled 3D structure, and the vitamin are highlighted in red,
green, and yellow colours, respectively. Arrows highlighted in blue colour denote the workflows in the training stage, while arrows in black
colour denote the workflows in the prediction stage.
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subsequent descriptions.
Strategy II: Threshold that maximises the value ofMCC
Because the MCC provides the overall measurement
of the quality of the binary predictions, we thus reported
the threshold-dependent evaluation indexes by choosing
the threshold, denoted as TMaxMCC, which maximises
the value of MCC of predictions. Similarly, for conveni-
ence, the evaluation results obtained under TMaxMCC will
be termed as MaxMCC Evaluation.
In addition, to evaluate the overall prediction quality
of a prediction model, the AUC, which is the area under
the Receiver Operating Characteristic (ROC) curve and
is threshold-independent, was also taken.
Results and discussion
Inappropriate cross-validation will over-estimate
prediction performance
Cross-validation methods are often used to evaluate the
performance of a predictor [56,57]. Previous studies have
shown that the leave-one-out cross-validation (jack-knifetest) is most stringent [58-61]. However, leave-one-out
cross-validation is time-consuming, especially when a
dataset is huge and a complicated prediction algorithm
(such as SVM in this study) is used. Additionally, be-
cause we need make a fair comparison of the proposed
method with VitaPred [30], the five-fold cross-validation,
which was used by Panwar et al. [30] to evaluate VitaPred,
was also adopted in this study.
Another critical aspect that should be addressed here
is the method of performing five-fold cross-validation.
In fact, five-fold cross-validation can be performed at
two different levels for the considered protein-vitamin
binding residue prediction problem: (i) residue-level cross-
validation and (ii) sequence-level cross-validation.
Residue-level five-fold cross-validation is performed
as follows: residues in all the training protein sequences
are randomly partitioned into five equally sized, disjoint
subsets; then, one subset is used for testing, and the
remaining four subsets are used for training; this process
is continued until all the five subsets of the training data-
set are traversed.
Table 2 Performance comparisons between residue- and sequence-level five-fold cross-validations on DVI, DVAI, DVBI,
and DPLPI under Balanced Evaluation
Dataset Method Sn (%) Sp (%) Acc (%) MCC AUC TP TN FP FN
DVI VitaPred* 78.52 78.61 78.60 0.37 0.87 - - - -
SVM-R◇ 77.88 81.34 81.18 0.30 0.87 2349 50530 11592 667
SVM-S△ 77.65 80.16 80.04 0.29 0.87 2342 49797 12325 674
DVAI VitaPred* 72.70 76.89 76.51 0.32 0.83 - - - -
SVM-R◇ 73.98 77.94 77.67 0.30 0.85 398 5749 1627 140
SVM-S△ 72.12 76.34 76.06 0.28 0.82 388 5631 1745 150
DVBI VitaPred* 83.33 80.51 80.77 0.42 0.90 - - - -
SVM-R◇ 80.44 83.83 83.68 0.33 0.90 1785 42063 8116 434
SVM-S△ 79.86 82.90 82.77 0.32 0.89 1772 41598 8581 447
DPLPI VitaPred* 90.20 92.61 92.40 0.67 0.97 - - - -
SVM-R◇ 91.48 93.38 93.30 0.55 0.97 999 24874 1764 93
SVM-S△ 90.38 92.62 92.53 0.52 0.96 987 24672 1966 105
*Data obtained from [30].
◇SVM-R: The re-implementation of VitaPred over residue-level cross-validation.
△SVM-S: The re-implementation of VitaPred over sequence-level cross-validation.
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protein sequences, rather than training residues, are
randomly partitioned into five equally sized, disjoint
subsets; then, residues in one subset are used for test-
ing, and residues in the remaining four subsets are
used for training; this practice is continued until all the
five subsets of the training dataset are traversed.
In reference [30], Panwar et al. used residue-level cross-
validation to evaluate the performance of their VitaPred.
However, we believe that residue-level cross-validation
tends to over-estimate the performance of a prediction
model and is therefore inappropriate. Next, we will empir-
ically demonstrate this argument as follows:Table 3 Performance comparisons between residue- and sequ
and DPLPI under MaxMCC Evaluation
Dataset Method Sn (%) Sp (%) Acc (%)
DVI VitaPred* 52.19 96.79 92.73
SVM-R◇ 52.62 98.29 96.18
SVM-S△ 52.29 98.32 96.19
DVAI VitaPred* 42.75 97.51 92.54
SVM-R◇ 43.49 96.39 92.80
SVM-S△ 40.15 96.39 92.57
DVBI VitaPred* 55.57 98.04 94.18
SVM-R◇ 58.77 98.45 96.77
SVM-S△ 58.18 98.40 96.69
DPLPI VitaPred* 79.76 98.62 96.91
SVM-R◇ 79.67 99.19 98.42
SVM-S△ 80.86 99.07 98.36
*Data excerpted from [30].
◇SVM-R: The re-implementation of VitaPred over residue-level cross-validation.
△SVM-S: The re-implementation of VitaPred over sequence-level cross-validation.Note that to objectively and fairly compare our results
with those obtained by VitaPred [30], the same machine-
learning model (i.e., SVM) and the same feature represen-
tation (i.e., 340-D PSSM feature) were also used in our
experiments.
For each of the four benchmark datasets (i.e., DVI,
DVAI, DVBI, and DPLPI), we performed residue- and
sequence-level five-fold cross-validations. Tables 2 and
3 summarise the performance comparisons between
residue- and sequence-level five-fold cross-validations on
the four benchmark datasets under Balanced Evaluation
and MaxMCC Evaluation, respectively. Note that in
Tables 2 and 3, SVM-R and SVM-S denote the resultsence-level five-fold cross-validations on DVI, DVAI, DVBI,
MCC AUC TP TN FP FN
0.53 0.87 - - - -
0.54 0.87 1586 61063 1059 1430
0.54 0.87 1577 61076 1046 1439
0.48 0.83 - - - -
0.41 0.85 234 7110 266 304
0.39 0.82 216 7109 267 322
0.61 0.90 - - - -
0.59 0.90 1304 49401 778 915
0.58 0.89 1291 49373 806 928
0.81 0.97 - - - -
0.79 0.97 870 26422 216 222
0.79 0.96 883 26391 247 209
Table 4 Performance comparisons between PSSM + PSSs + VBPs and PSSM features on DVI, DVAI, DVBI, and DPLPI
datasets over five-fold sequence-level cross-validation under Balanced Evaluation
Dataset Feature Sn (%) Sp (%) Acc (%) MCC AUC TP TN FP FN
DVI PSSM 77.65 80.16 80.04 0.29 0.87 2342 49797 12325 674
PSSM + PSSs + VBPs 78.55 82.02 81.86 0.31 0.88 2369 50951 11171 647
DVAI PSSM 72.12 76.34 76.06 0.28 0.82 388 5631 1745 150
PSSM + PSSs + VBPs 72.12 78.28 77.86 0.29 0.84 388 5774 1602 150
DVBI PSSM 79.86 82.90 82.77 0.32 0.89 1772 41598 8581 447
PSSM + PSSs + VBPs 80.71 85.14 84.96 0.35 0.90 1791 42724 7455 428
DPLPI PSSM 90.38 92.62 92.53 0.52 0.96 987 24672 1966 105
PSSM + PSSs + VBPs 91.48 93.09 93.03 0.54 0.97 999 24798 1840 93
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respectively.
In Table 2, it can be observed that the values of Sn, Sp,
Acc, MCC, and AUC for SVM-R are consistently superior
to those for SVM-S throughout the four benchmark data-
sets. Taking MCC as an example, SVM-R clearly outper-
forms SVM-S, and an average improvement of 2% was
observed on the four benchmark datasets. Similar results
can also be observed in Table 3. From the comparison re-
sults between SVM-R and SVM-S on the four considered
datasets listed in Tables 2 and 3, we empirically demon-
strated that the residue-level cross-validation does over-
estimate the performance of a prediction model. We
speculate that the main reason for this over-estimation is
that during the residue-level cross-validation, some testing
residues and training residues may originate from the
same protein sequence and thus have much higher hom-
ology, which will lead to a better prediction performance.
On the other hand, SVM-R is in fact a re-implementation
of VitaPred [30] because the prediction model and feature
representation used in SVM-R are exactly the same as
those used in VitaPred. By revisiting Tables 2 and 3, we can
find that the AUC values for SVM-R on the four bench-
mark datasets are 0.87, 0.85, 0.90, and 0.97, which are equal
to that for VitaPred with only one minor exception (i.e.,
0.85 and 0.83 for SVM-R and VitaPred, respectively, in theTable 5 Performance comparisons between PSSM + PSSs + VBP
five-fold sequence-level cross-validation under MaxMCC Evalu
Dataset Feature Sn (%) Sp (%) Acc (%
DVI PSSM 52.29 98.32 96.19
PSSM + PSSs + VBPs 53.22 98.32 96.23
DVAI PSSM 40.15 96.39 92.57
PSSM + PSSs + VBPs 44.24 96.61 93.05
DVBI PSSM 58.18 98.40 96.69
PSSM + PSSs + VBPs 59.58 98.33 96.69
DPLPI PSSM 80.86 99.07 98.36
PSSM + PSSs + VBPs 81.32 99.12 98.42DVAI dataset), showing that SVM-R and VitaPred achieved
almost equal overall prediction quality.
However, several abnormal phenomena are observed
when comparing the other four indexes, (i.e., Sn, Sp, Acc,
and MCC) between SVM-R and VitaPred. Using the results
in the DPLPI dataset under Balanced Evaluation as an ex-
ample (refer to Table 2), the values of Sn, Sp, and Acc for
VitaPred are 90.20%, 92.61%, and 92.40%, respectively,
which are obviously lower than those for SVM-R (i.e.,
91.48%, 93.38%, and 93.30%, respectively); however, the
value of MCC for VitaPred is, unexpectedly, approximately
12% higher than that for SVM-R. A similar phenomenon
can also be observed in the DVAI dataset. According to the
definitions of Sn, Sp, Acc, and MCC and the relationships
between them, this phenomenon should not appear. Based
on the comparison between SVM-R and VitaPred, we
speculate that the MCC reported in VitaPred [30] has been
over-estimated or over-optimised, which will be further
demonstrated in the subsequent independent validation test.
Considering that the residue-level cross-validation will
over-estimate the performance of a prediction model, to-
gether with the fact that VitaPred may possibly have
over-estimated the MCCs on benchmark datasets, we
will take SVM-S (i.e., a re-implementation of VitaPred)
over sequence-level cross-validation evaluation, rather
than VitaPred itself, as the baseline predictor tos and PSSM on DVI, DVAI, DVBI, and DPLPI datasets over
ation
) MCC AUC TP TN FP FN
0.54 0.87 1577 61076 1046 1439
0.55 0.88 1605 61080 1042 1411
0.39 0.82 216 7109 267 322
0.43 0.84 238 7126 250 300
0.58 0.89 1291 49373 806 928
0.59 0.90 1322 49342 837 897
0.79 0.96 883 26391 247 209
0.79 0.97 888 26403 235 204
Figure 2 ROC curves of the predictions with PSSM and PSSM +
PSSs + VBPs features, respectively, on the DVI dataset over
sequence-level five-fold cross-validation.
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in the subsequent experiments.
Improving prediction performance by combining the
features of PSSM, PSSs, and VBPs
In this section, we will demonstrate that the perform-
ance of protein-vitamin interaction prediction can be
further improved by combining the features of PSSM,
PSSs, and VBPs. The features of 340-D PSSM, 51-D
PSSs, and 17-D VBPs are serially combined to form a
408-D discriminative feature, denoted as PSSM + PSSs +
VBPs. We then evaluated the SVM-S with the PSSM +
PSSs + VBPs feature as a model input on each of the
four benchmark datasets over five-fold sequence-level
cross-validation. Tables 4 and 5 summarise the perform-
ance comparisons between the PSSM + PSSs + VBPs and
PSSM features under Balanced Evaluation and MaxMCC
Evaluation, respectively. From Tables 4 and 5, we can see
that the prediction performances are indeed improved on
all the four benchmark datasets after incorporating
PSSs and VBPs features into the PSSM feature underTable 6 Performance comparisons between with- and withou
five-fold sequence-level cross-validation under Balanced Eval
Dataset Ensemble Sn (%) Sp (%) Acc (%)
DVI No 78.55 82.02 81.86
Yes 78.45 84.17 83.90
DVAI No 72.12 78.28 77.86
Yes 72.68 79.89 79.40
DVBI No 80.71 85.14 84.96
Yes 81.34 85.49 85.31
DPLPI No 91.48 93.09 93.03
Yes 91.30 93.65 93.56both Balanced Evaluation and MaxMCC Evaluation.
Taking MCC, which is the overall measurement of the
quality of the binary predictions, as an example, an
average improvement of 1.5% was observed under both
Balanced Evaluation and MaxMCC Evaluation. In
terms of the AUC, which measures the overall predic-
tion quality of a prediction mode, an average improve-
ment of 1% was also observed. Figure 2 illustrates the
ROC curves of the predictions with PSSM and PSSM +
PSSs + VBPs features, respectively, on the DVI dataset
over sequence-level five-fold cross-validation.
We have also provided performance comparisons of
different feature combinations in Additional file 2: Table S1.
Ensembling heterogeneous SVMs helps to improve the
prediction performance
In this section, we will empirically demonstrate that the
prediction performance of protein-vitamin interactions
can be further improved by ensembling multiple hetero-
geneous SVMs. More specifically, we adopted three fea-
ture selection methods (i.e., data variance [49], Fisher
score [50], and Laplacian score [51]) to select three dif-
ferent feature subsets from the original PSSM + PSSs +
VBPs feature space; then, we trained three heteroge-
neous SVMs on the selected feature subsets. The final
prediction was performed by averaging the outputs of
the three trained SVMs. For comparison, we also directly
trained an SVM with the original PSSM + PSSs +VBPs
feature, denoted as no ensemble. Table 6 summarises the
performance comparisons between ensemble and no en-
semble on all the four considered datasets over sequence-
level five-fold cross-validation under Balanced Evaluation.
Figure 3 illustrates the ROC curves of the predictions
with ensemble and no ensemble, respectively, on the DVI
dataset over sequence-level five-fold cross-validation.
In Table 6, it can be observed that the values of the five
evaluation indexes (i.e., Sn, Sp, Acc, MCC, and AUC) of
the prediction under ensemble are consistently superior to
that of the prediction under no ensemble, with only two
exceptions: Sn in the DVI and DPLPI datasets. Thet-ensemble on DVI, DVAI, DVBI, and DPLPI datasets over
uation
MCC AUC TP TN FP FN
0.31 0.88 2369 50951 11171 647
0.34 0.89 2366 52285 9837 650
0.29 0.84 388 5774 1602 150
0.31 0.85 391 5893 1483 147
0.35 0.90 1791 42724 7455 428
0.36 0.91 1805 42898 7281 414
0.54 0.97 999 24798 1840 93
0.56 0.97 997 24947 1691 95
























No Ensemble (AUC = 0.88)
Ensemble (AUC = 0.89)
Figure 3 ROC curves of the predictions with ensemble and no ensemble, respectively, on the DVI dataset over sequence-level
five-fold cross-validation.
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ments of approximately 2% and 1% for MCC and AUC,
respectively. The results demonstrate that the heteroge-
neous SVMs trained with different feature subsets can
complement with each other, which accounts for the im-
provements in the prediction performance.
Comparison with existing protein-vitamin interaction
predictors
In this section, we will compare the proposed method,
called TargetVita, with existing predictors for protein-
vitamin prediction. Note that in TargetVita, the PSSM +
PSSs + VBPs feature was used as the input feature, and the
SVM ensemble based on feature selection was applied. To
the best of our knowledge, VitaPred [30] is the only pre-
dictor that was specifically designed for protein-vitaminTable 7 Performance comparisons with SVM-S on DVI, DVAI,
cross-validation under Balanced Evaluation
Dataset Method Sn (%) Sp (%) Acc (%)
DVI SVM-S△ 77.65 80.16 80.04
TargetVita 78.45 84.17 83.90
DVAI SVM-S△ 72.12 76.34 76.06
TargetVita 72.68 79.89 79.40
DVBI SVM-S△ 79.86 82.90 82.77
TargetVita 81.34 85.49 85.31
DPLPI SVM-S△ 90.38 92.62 92.53
TargetVita 91.30 93.65 93.56
△SVM-S: The re-implementation of VitaPred over sequence-level cross-validation.prediction; thus, we compare the proposed TargetVita with
VitaPred under both a cross-validation test and an inde-
pendent validation test.
However, the cross-validation performance of VitaPred
may have been overestimated because it was evaluated
by performing residue-level cross-validation. In view of
this, SVM-S, which is a re-implementation of VitaPred
that was evaluated over sequence-level cross-validation,
was taken to compare with the proposed TargetVita
when performing the cross-validation test. As for the in-
dependent validation test, TargetVita will be compared
with both VitaPred and the SVM-S.
A. Cross-validation test
Tables 7 and 8 illustrate the performance comparisons be-
tween TargetVita and SVM-S on the four datasets overDVBI, and DPLPI datasets over five-fold sequence-level
MCC AUC TP TN FP FN
0.29 0.87 2342 49797 12325 674
0.34 0.89 2366 52285 9837 650
0.28 0.82 388 5631 1745 150
0.31 0.85 391 5893 1483 147
0.32 0.89 1772 41598 8581 447
0.36 0.91 1805 42898 7281 414
0.52 0.96 987 24672 1966 105
0.56 0.97 997 24947 1691 95
Table 8 Performance comparisons with existing predictors on DVI, DVAI, DVBI, and DPLPI datasets over five-fold
sequence-level cross-validation under MaxMCC Evaluation
Dataset Method Sn (%) Sp (%) Acc (%) MCC AUC TP TN FP FN
DVI SVM-S△ 52.29 98.32 96.19 0.54 0.87 1577 61076 1046 1439
TargetVita 51.06 98.59 96.39 0.55 0.89 1540 61244 878 1476
DVAI SVM-S△ 40.15 96.39 92.57 0.39 0.82 216 7109 267 322
TargetVita 44.43 96.81 93.25 0.44 0.85 239 7141 235 299
DVBI SVM-S△ 58.18 98.40 96.69 0.58 0.89 1291 49373 806 928
TargetVita 56.21 98.81 97.02 0.60 0.91 1248 49582 597 971
DPLPI SVM-S△ 80.86 99.07 98.36 0.79 0.96 883 26391 247 209
TargetVita 74.05 99.61 98.60 0.80 0.97 812 26534 104 280
△SVM-S: The re-implementation of VitaPred over sequence-level cross-validation.
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Evaluation and MaxMCC Evaluation, respectively. From
Table 7, we can see that the values of the five evaluation in-
dexes for TargetVita are consistently superior to that of
SVM-S throughout the four benchmark datasets. Taking
MCC and AUC as examples, which are the two indexes
measuring the overall prediction performance of a pre-
dictor, TargetVita clearly outperforms SVM-S, and average
improvements of 3.5% and 2% were observed, respectively.
Under MaxMCC Evaluation (refer to Table 8), a similar
phenomenon can also be observed, with only minor excep-
tions on Sn.
B. Independent validation test
Performing only cross-validation comparisons to demon-
strate the effectiveness of a newly developed method over
an existing method is often not convincing, the reason be-
ing that the characteristics of the new method may be
over-fitted and/or over-optimised to the underlying dataset
for the purpose of pursuing positive comparison resultsTable 9 Performance comparisons with existing predictors on
Evaluation
Dataset Method Sn (%) Sp (%) Acc (%)
DVI VitaPred* 73.70 71.98 72.07
SVM-S△ 75.38 78.51 78.35
TargetVita 80.73 81.05 81.03
DVAI VitaPred* 73.48 72.87 72.93
SVM-S△ 73.48 79.25 78.61
TargetVita 79.01 79.18 79.16
DVBI VitaPred* 83.05 68.76 69.40
SVM-S△ 78.28 81.49 81.35
TargetVita 81.38 81.69 81.68
DPLPI VitaPred* 84.15 83.22 83.26
SVM-S△ 85.77 90.18 90.00
TargetVita 89.02 89.30 89.29
*Data excepted from [30].
△SVM-S: The re-implementation of VitaPred.[21,62,63]. Validation on fresh independent data has been
considered as an important and necessary procedure
when comparing different methods, and it has been widely
applied in related research.
With this view, we also performed independent valid-
ation tests to further demonstrate the superiority of the
proposed TargetVita over existing protein-vitamin pre-
dictors. Tables 9 and 10 summarise the performance
comparisons between TargetVita and existing predictors
on independent validation tests under Balanced Evalu-
ation and MaxMCC Evaluation, respectively. From
Tables 9 and 10, two observations can be made as follows:
First, the proposed TargetVita significantly outperforms
VitaPred under both Balanced Evaluation and MaxMCC
Evaluation. Taking MCC as an example, TargetVita
achieved approximately 9% ~ 11% and 6%~ 20% improve-
ments on the four independent validation datasets under
Balanced Evaluation and MaxMCC Evaluation, respect-
ively. In addition, TargetVita also outperformed SVM-S,
which is a re-implementation of VitaPred, and acted as thethe independent validation datasets under Balanced
MCC AUC TP TN FP FN
0.22 - - - - -
0.28 0.85 493 9167 2509 161
0.33 0.89 528 9463 2213 126
0.31 - - - - -
0.38 0.83 133 1142 299 48
0.41 0.86 143 1141 300 38
0.23 - - - - -
0.30 0.88 328 7291 1656 91
0.32 0.90 341 7309 1638 78
0.33 - - - - -
0.44 0.95 211 5352 583 35
0.44 0.96 219 5300 635 27
Table 10 Performance comparisons with existing predictors on the independent validation datasets under MaxMCC
Evaluation
Dataset Method Sn (%) Sp (%) Acc (%) MCC AUC TP TN FP FN
DVI VitaPred* 41.74 96.63 93.72 0.38 - - - - -
SVM-S△ 47.09 98.40 95.68 0.52 0.85 308 11489 187 346
TargetVita 47.01 98.42 95.69 0.52 0.89 308 11491 185 346
DVAI VitaPred* 30.39 97.22 89.77 0.37 - - - - -
SVM-S△ 32.04 97.09 89.83 0.38 0.83 58 1399 42 123
TargetVita 38.12 96.81 90.26 0.43 0.86 69 1395 46 112
DVBI VitaPred* 49.40 94.49 92.47 0.35 - - - - -
SVM-S△ 52.03 98.25 96.18 0.53 0.88 218 8790 157 201
TargetVita 51.06 98.69 96.56 0.55 0.90 214 8830 117 205
DPLPI VitaPred* 65.85 98.40 97.10 0.63 - - - - -
SVM-S△ 72.76 99.11 98.06 0.74 0.95 179 5882 53 67
TargetVita 74.39 99.07 98.09 0.75 0.96 183 5880 55 63
*Data excepted from [30].
△SVM-S: The re-implementation of VitaPred.
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mately 2.5% for MCC if compared with the second best
performer, SVM-S.
Second, the values of MCC for VitaPred over the cross-
validation test and independent validation test differ signifi-
cantly under both the Balanced Evaluation and MaxMCC
Evaluation if compared withTargetVita and SVM-S. In other
words, the performance evaluated over the cross-validation
test is significantly better than that evaluated over the inde-
pendent validation test for VitaPred, while similar perfor-
mances were obtained over the cross-validation test and the
independent validation test for TargetVita and SVM-S.
Taking the results under MaxMCC Evaluation as an




















Figure 4 Differences between the MCC values over the
cross-validation test and over the independent validation test
for VitaPred, SVM-S, and TargetVita on the four considered
vitamins under MaxMCC Evaluation.test for VitaPred are 0.53, 0.48, 0.61, and 0.81, respect-
ively (refer to Table 3), while the values of MCC over the
independent validation test for VitaPred are 0.38, 0.37,
0.35, and 0.63, respectively (refer to Table 10), for the
four considered vitamins. Then, we can calculate that
the MCC differences between the cross-validation test
and the independent validation test of VitaPred for the
four considered vitamins are 0.15, 0.11, 0.26, and 0.18,
respectively. By revisiting Table 8, together with
Table 10, we calculate that the MCC differences be-
tween the cross-validation test and the independent
validation test of the proposed TargetVita for the four
considered vitamins are only 0.03, 0.01, 0.05, and 0.05,
respectively. Similarly, the MCC differences of SVM-S
can also be calculated from Table 3 and Table 10.
Figure 4 illustrates the differences between the MCC
values over the cross-validation test and the independent
validation test for VitaPred, SVM-S, and TargetVita on the
four considered vitamins underMaxMCC Evaluation. Note
that in Figure 4, dV, dS, and dT denote the MCC differences
for VitaPred, SVM-S, and TargetVita, respectively, and only
the MCC differences on the DPLPI dataset are explicitly
labelled.
From Figure 4, we can intuitively find that the proposed
TargetVita and SVM-S achieve similar performances (in
terms of MCC) over both the cross-validation test and in-
dependent validation test, as their MCC differences are
small, while the performance of VitaPred over the in-
dependent validation test is significantly lower than
that that over the cross-validation test with all four
considered vitamins, indicating that the performance of
VitaPred over the cross-validation test has potentially
been over-estimated or over-optimised, thus leading to
a lower generalisation capability (i.e., poor performance
Yu et al. BMC Bioinformatics 2014, 15:297 Page 13 of 14
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supports the speculation (i.e., the MCC of VitaPred has
potentially been over-estimated) we made in a previous
section.
C. Performance on a non-vitamin binding dataset
We then performed performance comparisons between
the proposed TargetVita and VitaPred on the non-vitamin
binding dataset NVD, and the results of the comparison
are listed in Additional file 2: Table S2. Note that the re-
sults of VitaPred and TargetVita were obtained by feeding
the 6676 sequences to their corresponding web servers
with default threshold settings.
From Table S2, we can clearly see that the proposed
TargetVita achieved much better prediction perform-
ance than VitaPred. Among the 1852390 residues in
the 6676 non-vitamin binding sequences, 46319 resi-
dues were mistakenly predicted as binding residues by
VitaPred, while only 36361 false positives were obtained
by TargetVita.
Conclusions
In this study, we have designed and implemented a new
sequence-based predictor, called TargetVita, for protein-
vitamin binding residue prediction. TargetVita performs
prediction by utilising multiple features derived from
protein sequences and effectively ensembling heteroge-
neous SVMs trained on different feature subspaces. Ex-
perimental results on benchmark datasets demonstrated
that the proposed TargetVita can achieve good perform-
ance and is superior to existing protein-vitamin binding
residue predictors.
Our future work will focus on further improving the
prediction performance of TargetVita by uncovering new
effective feature sources and applying more powerful
machine-learning algorithms.
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